NextCure, Inc. (NXTC)
NXTC Stock Price Chart
Explore NextCure, Inc. interactive price chart. Choose custom timeframes to analyze NXTC price movements and trends.
NXTC Company Profile
Discover essential business fundamentals and corporate details for NextCure, Inc. (NXTC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 May 2019
Employees
43.00
Website
https://www.nextcure.comCEO
Michael S. Richman
Description
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
NXTC Financial Timeline
Browse a chronological timeline of NextCure, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$1.98.
Earnings released on 7 May 2026
EPS came in at -$1.87 falling short of the estimated -$1.81 by -3.31%.
Earnings released on 5 Mar 2026
EPS came in at -$0.81 surpassing the estimated -$2.26 by +64.16%.
Earnings released on 5 Nov 2025
EPS came in at -$3.22 surpassing the estimated -$4.06 by +20.69%.
Earnings released on 7 Aug 2025
EPS came in at -$11.29 falling short of the estimated -$4.62 by -144.37%.
Stock split effective on 14 Jul 2025
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 1 May 2025
EPS came in at -$4.68 surpassing the estimated -$4.80 by +2.50%.
Earnings released on 6 Mar 2025
EPS came in at -$4.92 falling short of the estimated -$4.08 by -20.59%.
Earnings released on 7 Nov 2024
EPS came in at -$4.92 falling short of the estimated -$4.20 by -17.14%.
Earnings released on 1 Aug 2024
EPS came in at -$6.60 falling short of the estimated -$4.32 by -52.78%.
Earnings released on 2 May 2024
EPS came in at -$7.32 falling short of the estimated -$5.40 by -35.56%.
Earnings released on 21 Mar 2024
EPS came in at -$6.24 surpassing the estimated -$6.48 by +3.70%.
Earnings released on 2 Nov 2023
EPS came in at -$6.12 surpassing the estimated -$7.68 by +20.31%.
Earnings released on 3 Aug 2023
EPS came in at -$7.68 falling short of the estimated -$7.20 by -6.67%.
Earnings released on 4 May 2023
EPS came in at -$6.96 surpassing the estimated -$7.68 by +9.37%.
Earnings released on 2 Mar 2023
EPS came in at -$7.44 surpassing the estimated -$7.80 by +4.62%.
Earnings released on 3 Nov 2022
EPS came in at -$8.16 falling short of the estimated -$7.20 by -13.33%.
Earnings released on 4 Aug 2022
EPS came in at -$7.80 surpassing the estimated -$8.76 by +10.96%.
Earnings released on 5 May 2022
EPS came in at -$8.88 falling short of the estimated -$8.16 by -8.82%.
Earnings released on 3 Mar 2022
EPS came in at -$7.32 surpassing the estimated -$8.04 by +8.96%.
Earnings released on 4 Nov 2021
EPS came in at -$7.80 surpassing the estimated -$8.04 by +2.99%.
Earnings released on 5 Aug 2021
EPS came in at -$7.80 falling short of the estimated -$7.20 by -8.33%.
NXTC Stock Performance
Access detailed NXTC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
